DACS
BBIO icon

Dymon Asia Capital (Singapore)’s BridgeBio Pharma BBIO Stock Holding History

Dymon Asia Capital (Singapore)’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-17,500
Closed -$292K – 131
2021
Q4 		$292K Buy
+17,500
New +$740K 0.03% 98

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dymon Asia Capital (Singapore)'s BBIO Position: Q1 2022 in Review

Dymon Asia Capital (Singapore) sold out of BridgeBio Pharma (BBIO) in Q1 2022, closing a stake of 17,500 shares — an estimated $292K sold.

Dymon Asia Capital (Singapore) first reported a position in BBIO in Q4 2021 and held it in 1 quarter. The position peaked at $292K in Q4 2021. 178 funds tracked by Wall St. Rank hold BBIO as of Q1 2022.

  • Dymon Asia Capital (Singapore) reported no remaining BridgeBio Pharma position as of Q1 2022 after selling out during the quarter.
  • Dymon Asia Capital (Singapore) sold 17,500 BridgeBio Pharma shares in Q1 2022, an estimated $292K.
  • Dymon Asia Capital (Singapore) first reported a position in BridgeBio Pharma in Q4 2021 and held it in 1 quarter.
  • Dymon Asia Capital (Singapore)'s BridgeBio Pharma position peaked at $292K in Q4 2021.
  • 178 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2022.

Based on Dymon Asia Capital (Singapore)'s 13F filing for Q1 2022, filed 13 May 2022.